Blue Cross NC Omalizumab Coverage Update

Coverage and Medical Necessity Criteria

Initial Therapy - Asthma

Covered when ALL of the following are met:

Asthma initial criteria: 1. Diagnosis of moderate to severe persistent asthma; AND 2. Age ≥6 years; AND 3. Pre-treatment total serum IgE within age-specific range with medical record documentation: ages 6–11: 30–1300 IU/mL OR age ≥12: 30–700 IU/mL; AND 4. Positive skin test or in vitro reactivity to a perennial aeroallergen; AND 5. Currently treated with and adherent to maximally tolerated conventional therapies, including BOTH: (a) an inhaled corticosteroid regimen for the past 3 months; AND (b) a regimen containing either a LABA, LTRA, LAMA, theophylline, or zileuton for the past 3 months — or documentation of clinical intolerance/contraindication to inhaled corticosteroids or to all listed controllers as specified; AND 6. History of inadequately controlled asthma despite adherence demonstrated by ONE of: (i) ≥2 severe exacerbations requiring systemic corticosteroid bursts in the past 12 months; OR (ii) ≥1 serious exacerbation requiring hospitalization, mechanical ventilation, ED, or urgent care in the past 12 months; OR (iii) asthma controlled that worsens when corticosteroids are tapered; OR (iv) baseline FEV1 <80% predicted; AND 7. Patient will continue asthma control therapy (e.g., inhaled corticosteroids ± other controllers) in combination with omalizumab; AND 8. Prescriber is a specialist or has consulted one; AND 9. Patient will not receive another biologic immunomodulator for the same indication; AND 10. No FDA labeled contraindications to omalizumab; AND 11. If requesting provider-administered formulation, patient inability to self-administer PLUS lack of caregiver support documented; AND 12. Requested quantity does not exceed indication-specific maximum units; AND 13. Site-of-Care criteria applies for inpatient/outpatient hospital administration when relevant.

Initial Therapy - Chronic Spontaneous Urticaria (CSU)

Covered when ALL of the following are met:

CSU initial criteria: 1. Diagnosis of chronic spontaneous urticaria (CSU); AND 2. Age ≥12 years; AND 3. Hives and itching present for ≥6 weeks with medical record documentation; AND 4. If on medications known to cause or worsen urticaria, prescriber has reduced/discontinued them or documents why dose reduction/discontinuation is not clinically appropriate; AND 5. Trial and inadequate response to an FDA‑labeled maximum dose of ONE second‑generation H1 antihistamine for at least a 2‑week trial OR documented intolerance/hypersensitivity/contraindication to second‑generation H1 antihistamines; AND 6. Requested dose is within FDA‑labeled dosing and does NOT exceed 300 mg every 4 weeks; AND 7. Prescriber is a specialist or has consulted one; AND 8. Patient will not receive another biologic immunomodulator for the same indication; AND 9. No FDA labeled contraindications to omalizumab; AND 10. If requesting provider‑administered formulation, inability to self‑administer PLUS lack of caregiver documented; AND 11. Requested quantity does not exceed maximum units allowed; AND 12. Site‑of‑Care criteria applies as applicable.

Initial Therapy - Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Covered when ALL of the following are met:

CRSwNP initial criteria: 1. Diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP); AND 2. Age ≥18 years; AND 3. Presence of at least TWO inadequately controlled symptoms (nasal obstruction/congestion, nasal discharge, facial pain/pressure, reduction or loss of smell) for ≥12 consecutive weeks prior to therapy initiation; AND 4. Diagnostic confirmation by anterior rhinoscopy OR nasal endoscopy OR CT of the sinuses (medical record documentation required); AND 5. Either prior nasal polyp surgery (e.g., adenoidectomy, functional endoscopic sinus surgery) OR documentation that patient is not a candidate for sinus surgery; AND 6. Trial and inadequate response to an intranasal corticosteroid for at least 4 consecutive weeks within 12 weeks prior to initiation OR documented intolerance/contraindication to intranasal corticosteroids OR patient currently being treated with and will continue intranasal corticosteroid therapy; AND 7. Prescriber is a specialist or has consulted one; AND 8. Patient will not receive another biologic immunomodulator for the same indication; AND 9. No FDA labeled contraindications to omalizumab; AND 10. If requesting provider‑administered formulation, inability to self‑administer PLUS lack of caregiver documented; AND 11. Requested quantity does not exceed maximum units allowed; AND 12. Site‑of‑Care criteria applies as applicable.

Initial Therapy - IgE-mediated Food Allergy

Covered when ALL of the following are met:

Food allergy initial criteria: 1. Diagnosis of IgE‑mediated food allergy; AND 2. Age ≥1 year; AND 3. Intended use in conjunction with food allergen avoidance; AND 4. Prescriber is a specialist or has consulted one; AND 5. Patient will not receive another biologic immunomodulator for the same indication; AND 6. No FDA labeled contraindications to omalizumab; AND 7. If requesting provider‑administered formulation, inability to self‑administer PLUS lack of caregiver documented; AND 8. Requested quantity does not exceed maximum units allowed; AND 9. Site‑of‑Care criteria applies as applicable.

Continuation Therapy

Covered when ALL of the following are met:

Continuation criteria general: 1. Previously approved through Blue Cross NC initial criteria OR would have met initial criteria at therapy start; AND 2. For asthma: documentation of improvement or stabilization from baseline indicated by ONE or more of decreased rescue medication use, decreased exacerbation frequency, increased predicted FEV1, or reduction in asthma‑related symptoms; AND patient currently treated and compliant with asthma control therapy; AND 3. For CSU: documented positive clinical response (e.g., reduced itch severity or hive count) AND requested dose remains within FDA labeled dosing and does NOT exceed 300 mg every 4 weeks; AND 4. For CRSwNP: documented positive clinical response (e.g., improved nasal congestion/obstruction, reduced nasal polyp score, improved CT score, improved sense of smell) AND either continuing intranasal corticosteroid therapy or documented intolerance/contraindication to all intranasal steroids; AND 5. For food allergy: documented reduction in dose‑limiting symptoms and continued use with food avoidance; AND 6. Patient is not being treated for acute bronchospasm, status asthmaticus, allergic rhinitis, or emergency allergic reactions including anaphylaxis; AND 7. Prescriber is a specialist or has consulted one; AND 8. Patient will not receive another biologic immunomodulator for the same indication; AND 9. No FDA labeled contraindications to omalizumab; AND 10. If requesting provider‑administered formulation, inability to self‑administer PLUS lack of caregiver documented; AND 11. Requested quantity does not exceed maximum units allowed; AND 12. Site‑of‑Care criteria applies as applicable.

CRSwNP Initial Therapy

CRSwNP initial therapy covered when ALL of the following are met:

CRSwNP initial: 1) Presence of at least 2 inadequately controlled symptoms for at least 12 consecutive weeks prior to therapy initiation; AND 2) Diagnostic confirmation by anterior rhinoscopy, nasal endoscopy, or sinus CT imaging; AND 3) Trial of an intranasal corticosteroid for at least 4 consecutive weeks within 12 weeks prior to therapy initiation OR documented intolerance/contraindication to intranasal corticosteroids OR patient currently being treated with and will continue intranasal corticosteroid therapy; AND 4) Documentation of prior nasal polyp surgery or documentation that patient is not a candidate for sinus surgery (as applicable).

Removed prior requirement for trial/failure of Xhance or oral systemic corticosteroids; examples of nasal polyp surgery listed in policy.

CRSwNP Continuation Therapy

CRSwNP continuation covered when ALL of the following are met:

CRSwNP continuation: 1) Documented demonstration of positive clinical response to omalizumab since initiation (e.g., improved nasal congestion/obstruction, reduced nasal polyp score, improved CT score, improved sense of smell); AND 2) Patient is continuing intranasal corticosteroid therapy while on omalizumab OR has documented intolerance/contraindication to all intranasal corticosteroids; AND 3) Other standard continuation documentation per policy (e.g., adherence, required medical record documentation).

Continuation criteria adjusted to require documented positive clinical response and continuation of intranasal corticosteroid therapy.

Asthma

Covered when ALL of the following are met:

Asthma initial: Requires documentation of uncontrolled disease despite adherence to asthma control therapy; patient must be on maximally tolerated conventional therapies for the past 3 months including an inhaled corticosteroid regimen AND a regimen containing a LABA, LTRA, LAMA, theophylline, or zileuton; patient will continue asthma control therapy in combination with omalizumab (Xolair).

Asthma continuation: Documentation demonstrating improvement or stabilization from baseline (e.g., decreased rescue medication use, decreased exacerbation frequency, increased predicted FEV1, or reduction in asthma‑related symptoms) AND current adherence to asthma control therapy.

Chronic Spontaneous Urticaria

Chronic spontaneous urticaria (CSU) initial and continuation:

CSU initial: Symptoms present for at least 6 weeks with medical record documentation; required trial of a second‑generation H1 antihistamine at an FDA‑labeled maximum dose (with inadequate response) or documented intolerance/contraindication; prescriber must reduce/discontinue medications known to cause/worsen urticaria when appropriate or document why not clinically appropriate; dosing must be within FDA labeling and not exceed 300 mg every 4 weeks; prescriber is specialist or has consulted one.

CSU continuation: Demonstration of positive clinical response (e.g., reduction in itch severity or hive count) with medical record documentation; requested dose must remain within FDA labeled dosing and NOT exceed 300 mg every 4 weeks.

IgE-mediated Food Allergy

Covered when ALL of the following are met:

Food allergy initial: 1. Diagnosis of IgE‑mediated food allergy; AND 2. Age ≥1 year; AND 3. Intended use in conjunction with food allergen avoidance; AND 4. Prescriber is a specialist or has consulted one; AND 5. Documented reduction in dose‑limiting symptoms during continuation (for continuation requests); AND 6. Patient will continue to use the requested agent in conjunction with food allergen avoidance; AND 7. Not receiving another biologic immunomodulator for the same indication; AND 8. No FDA labeled contraindications; AND 9. If requesting provider‑administered formulation, inability to self‑administer PLUS lack of caregiver documented; AND 10. Requested quantity does not exceed maximum units allowed; AND 11. Site‑of‑Care criteria applies as applicable.

Food allergy note: New indication added for patients 1 year and older with corresponding dosing table and maximum units (March 2024).

Omalizumab (Xolair) is not indicated for emergency treatment. Specifically, this policy excludes use for the emergency treatment of allergic reactions, including anaphylaxis, and for relief of acute bronchospasm or status asthmaticus. The agent is also not covered for other forms of urticaria outside of chronic spontaneous urticaria (CSU). These limitations align with the FDA labeled uses and the policy's scope of approved indications.

Concomitant administration of omalizumab with other biologic immunomodulators for the same indication is prohibited. The policy lists specific examples of disallowed combinations and has been updated to include newer agents such as remibrutinib (Rhapsido). Providers must confirm the member is not receiving another biologic immunomodulator (e.g., benralizumab, depemokimab, dupilumab, mepolizumab, reslizumab, remibrutinib, tezepelumab-ekko) when requesting coverage.

Site-of-care rules apply to requests for facility-based administration. An inpatient admission solely for the purpose of administering an injection or infusion is not allowed; the inpatient stay must be for reasons other than administration of omalizumab. For outpatient hospital administration, the policy requires the medical necessity criteria plus at least one site-of-care bypass condition (for example, history of a severe adverse event, unstable comorbid condition, recent initiation of therapy, documented inability to adhere, or other specified clinical circumstances). If the site-of-care criteria are not met, administration should occur in a home infusion or physician office setting.

Requests that exceed the policy's dosing limits or that lack required prior or concurrent therapy documentation will be considered not medically necessary. For chronic spontaneous urticaria, for example, doses that exceed 300 mg every 4 weeks are outside covered limits. Similarly, failure to document required prior trials, ongoing concomitant therapies, or other mandated clinical information may lead to denial of coverage.

Prior Authorization, Documentation, and Step Therapy Actions

Prior Authorization

Prior Authorization Required

Prior authorization is required for the requested agent. Requests must meet the policy criteria and specify HCPCS/other applicable drug codes. Failure to obtain prior authorization may result in claim denial or delay.

Prior authorization required — requests must include HCPCS J2357 (if applicable) and relevant drug code(s).
Requests must meet all indication-specific criteria in the policy.

Prior Authorization

Prior Authorization — Indication-Specific Documentation

Prior authorization requests must include indication-specific documentation to support medical necessity. Missing or incomplete documentation may result in denial.

Diagnostic confirmation (see CRSwNP requirements below).
Documentation of prior and concurrent therapy trials and adherence.
Symptom duration and severity records where applicable.

Billing Codes, Dosing Limits, and Lab Requirements

Covered HCPCS CodesHCPCSCovered

J2357

Omalizumab injection, per 150 mg

Pre‑treatment serum total IgE — age-specific ranges

Age 6–11 pre-treatment total serum IgE30–1300 IU/mL

Age ≥12 pre-treatment total serum IgE30–700 IU/mL

Documentation requiredMedical record documentation of pre-treatment IgE level per age group is required

CSU dosing limit

CSU dosing limitRequested dose must not exceed 300 mg every 4 weeks

Dosing must be within FDA labeled dosingRequested dose must be within FDA labeled dosing for the indication

Documentation required

Definitions and Background

This policy defines the scope of coverage and key caveats: omalizumab is approved as an add-on maintenance therapy for specified, FDA‑labeled indications and is not for acute or emergency use. Prior authorization is required and requests must include indication‑specific documentation (diagnostic confirmation, prior/concurrent therapy trials and adherence, pre‑treatment IgE where applicable). Site-of-care criteria govern inpatient and outpatient hospital administration; inpatient admissions solely for administration are not acceptable. The policy also prohibits combination use with other biologic immunomodulators for the same indication and enforces indication‑specific dosing ceilings and required trials of conventional therapies.

Omalizumab (Xolair) is a monoclonal antibody that binds circulating IgE and is used as an add‑on maintenance therapy for several IgE‑mediated conditions. FDA‑approved indications include moderate‑to‑severe persistent asthma in patients aged ≥6 years with positive skin test or in vitro reactivity to a perennial aeroallergen, chronic spontaneous urticaria in patients aged ≥12 years who remain symptomatic despite H1 antihistamines, chronic rhinosinusitis with nasal polyps in adults with inadequate response to nasal corticosteroids, and IgE‑mediated food allergy in patients aged ≥1 year to reduce allergic reactions when used alongside avoidance. The drug is not intended for emergency treatment of allergic reactions, including anaphylaxis, nor for treatment of other forms of urticaria or relief of acute bronchospasm/status asthmaticus.

Positive clinical response — examples for continuation criteria

Asthma continuation response examplesDecrease in rescue medication use, decrease in exacerbation frequency, or increase in predicted FEV1 from pretreatment baseline

Policy Revision History

2026-07-01criteria_updateLatest

For CRSwNP: added requirement of ≥2 inadequately controlled symptoms for ≥12 consecutive weeks and diagnostic confirmation by anterior rhinoscopy, nasal endoscopy, or sinus CT; replaced prior Xhance/OCS trial requirement with an intranasal corticosteroid trial of ≥4 consecutive weeks within prior 12 weeks; added requirement for documented positive clinical response for CRSwNP continuation and that patients continue intranasal corticosteroid therapy.

2025-10-01criteria_update

Updated CRSwNP continuation criteria to require adherence to an over-the-counter intranasal steroid since starting Xolair; updated no-concomitant-use statements to include Rhapsido and added additional Site of Care bypass language.

OpenPayer

Omalizumab (Xolair) subcutaneous injection — Coverage Criteria

Coverage and Medical Necessity Criteria

Prior Authorization, Documentation, and Step Therapy Actions

Billing Codes, Dosing Limits, and Lab Requirements

Definitions and Background

Policy Revision History